Skip to main content
Clinical Trials/ACTRN12619001568101
ACTRN12619001568101
Recruiting
Phase 2

The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetes and Diabetic Microvascular Complications: Nephropathy, Retinopathy and Neuropathy

Monash University Malaysia0 sites116 target enrollmentNovember 13, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Monash University Malaysia
Enrollment
116
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Monash University Malaysia

Eligibility Criteria

Inclusion Criteria

  • 1\. Subject, or legal representative, has voluntarily signed and dated an Informed Consent Form.
  • 2\. Subject is 35\-75 years of age at screening date
  • 3\. Subject has T2DM with stable glucose control (not more than 10% change in HbA1c levels over the last 2 months) AND HbA1c range should be within 6\-9%
  • 4\. Subject has eGFR of 30\-89 AND has microalbuminuria as assessed by UACR of 20\-200mg/mmol, or
  • 5\. Mild/moderate retinopathy as defined by: Mild: At least one microaneurysm Moderate: Hemorrhage/microaneurysm, cotton wool spots, venous beading, and intraretinal
  • microvascular abnormalities
  • 6\. If subject has hypertension, he/she must have stable blood pressure control for the past 2 months with not more than 10% change and BP range should be \<145/90mmHg

Exclusion Criteria

  • 1\. Subject is pregnant during screening, OR planning to be pregnant, OR not on contraception
  • 2\. Subject has urine protein \>1\.5g/L during screening
  • 3\. Subject has current urinary tract infection during screening (symptomatic or definitively on urine FEME: pyuria, nitrites and red blood cells)
  • 4\. Subject has acute or severe chronic illness such as acute coronary syndrome, active tuberculosis, current history of cancer, liver or inflammatory disease etc.
  • 5\. Subject with unstable eye diseases such as media opacity and glaucoma
  • 6\. Subject has known non\-diabetic kidney disease, such as kidney stones etc
  • 7\. Patient has severe chronic kidney disease (Stage 4/5 CKD, eGFR \<30ml/min/1\.73m2\)
  • 8\. Subject is taking other water\-soluble antioxidants for the past 2 weeks or fat\-soluble antioxidants for the past 1 month
  • 9\. Subject is a heavy smoker (\>20 sticks/day) that is currently smoking or has stopped smoking for \<1 month

Outcomes

Primary Outcomes

Not specified

Similar Trials